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Abstract
Background: In vitro data suggest that changes in myocardial substrate metabolism may contribute
to impaired myocardial function in diabetic cardiomyopathy (DCM). The purpose of the present
study was to study in a rat model of early DCM, in vivo changes in myocardial substrate metabolism
and their association with myocardial function.
Methods: Zucker diabetic fatty (ZDF) and Zucker lean (ZL) rats underwent echocardiography
followed by [11C]palmitate positron emission tomography (PET) under fasting, and [18F]-2-fluoro-
2-deoxy-D-glucose PET under hyperinsulinaemic euglycaemic clamp conditions. Isolated
cardiomyocytes were used to determine isometric force development.
Results: PET data showed a 66% decrease in insulin-mediated myocardial glucose utilisation and a
41% increase in fatty acid (FA) oxidation in ZDF vs. ZL rats (both p < 0.05). Echocardiography
showed diastolic and systolic dysfunction in ZDF vs. ZL rats, which was paralleled by a significantly
decreased maximal force (68%) and maximal rate of force redevelopment (69%) of single
cardiomyocytes. Myocardial functional changes were significantly associated with whole-body
insulin sensitivity and decreased myocardial glucose utilisation. ZDF hearts showed a 68% decrease
in glucose transporter-4 mRNA expression (p < 0.05), a 22% decrease in glucose transporter-4
protein expression (p = 0.10), unchanged levels of pyruvate dehydrogenase kinase-4 protein
expression, a 57% decreased phosphorylation of AMP activated protein kinase α1/2 (p < 0.05) and
a 2.4-fold increased abundance of the FA transporter CD36 to the sarcolemma (p < 0.01) vs. ZL
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hearts, which are compatible with changes in substrate metabolism. In ZDF vs. ZL hearts a 2.4-fold
reduced insulin-mediated phosphorylation of Akt was found (p < 0.05).
Conclusion: Using PET and echocardiography, we found increases in myocardial FA oxidation
with a concomitant decrease of insulin-mediated myocardial glucose utilisation in early DCM. In
addition, the latter was associated with impaired myocardial function. These in vivo data expand
previous  in vitro findings showing that early alterations in myocardial substrate metabolism
contribute to myocardial dysfunction.
Background
Heart disease is the leading cause of death in patients with
type 2 diabetes mellitus (T2DM), even in the absence of
coronary artery disease and hypertension, which is
ascribed to diabetic cardiomyopathy (DCM) [1]. In partic-
ular, altered myocardial energy metabolism, resulting
from changes in substrate supply and utilisation, has been
proposed to contribute to the development of DCM [2,3].
The normal heart derives its energy mainly from oxidation
of fatty acids (FA) (60–70%), glucose (30–40%) and lac-
tate (10%) [1,4]. In contrast, T2DM is accompanied by
increased lipolysis, hypertriglyceridemia, and reduced
insulin-mediated myocardial glucose uptake and utilisa-
tion. This results in a shift of myocardial substrate use
towards even higher FA utilisation. Reduced carbohydrate
oxidation with a concomitant increase in FA oxidation
and myocardial dysfunction has been shown in vitro in
various experimental diabetic models with a severe meta-
bolic phenotype, using isolated working hearts [5-8],
whole-heart preparations [9] and 13C-nuclear magnetic
resonance [10].
In more advanced diabetes and in the presence of com-
promised myocardial function, such as in heart failure
and ischemia, altered myocardial substrate metabolism
may further aggravate function [11]. However, there is
limited knowledge regarding myocardial metabolic phe-
notype in relation to function in early diabetes. In the
Zucker diabetic fatty (ZDF) rat, myocardial dysfunction,
as determined by echocardiography, is mildly present at
14 weeks [12] and overt at 20 weeks [13], whereas these
myocardial functional alterations are absent at 7 weeks of
age [13]. However, these studies did not assess myocardial
substrate metabolism [12,13]. Interestingly, in spite of
alterations in myocardial carbohydrate metabolism, no
changes in systolic function were found in 11-weeks-old
ZDF rats [10]. Moreover, at 12 weeks of age, ZDF rats
showed increased FA oxidation and decreased carbohy-
drate oxidation with only a slight depression of systolic
function in vitro [9]. Taken together, these in vitro data sug-
gest that changes in myocardial substrate metabolism may
contribute to myocardial dysfunction, but in vivo evidence
is scarce. Detailed characterisation of alterations in myo-
cardial substrate metabolism in early diabetes in vivo may
increase insight in the pathophysiology of myocardial
dysfunction. Therefore, the purpose of the present study
was to investigate the relationship between myocardial
substrate metabolism and function in vivo in 14-weeks-
old ZDF rats using state-of-the-art techniques, including
[11C]palmitate and [18F]-2-fluoro-2-deoxy-D-glucose
(18FDG) positron emission tomography (PET) under con-
trolled conditions, together with in vivo echocardiography
and in vitro analysis of myocardial function. We found
increased myocardial FA oxidation with a concomitant
decrease of insulin-mediated myocardial glucose utilisa-
tion  in vivo, whereby the latter was associated with
impaired myocardial function in early DCM.
Methods
Animals
All experiments were approved by the Animal Care and
Use Committee of the VU University, and were conducted
in accordance with both the European Convention for the
Protection of Vertebrate Animals used for Experimental
and Other Scientific Purposes, and the Dutch Animal
Experimentation Act.
Male ZDF (fa/fa; n = 16) and age-matched Zucker lean
control rats (ZL; +/+; n = 12) were purchased from Charles
River Laboratories (Bruxelles, Belgium) at 11 weeks of age.
Rats were maintained on Teklad 2016 (Harlan, Horst, The
Netherlands), consisting of 16.7 wt% protein, 4.2 wt% fat
and 60.9 wt% carbohydrates, ad libitum. Animals were
housed in a temperature-controlled room (20–23°C; 40–
60% humidity) under a 12/12 h light/dark cycle starting
at 6.00 am. Body weight (BW), caloric intake and water
intake were determined on a weekly basis. At 14 weeks of
age, animals underwent echocardiography and PET. A
separate group of rats (n = 4 ZDF rats, n = 4 ZL rats)
received insulin stimulation through an i.p. injection of
10 U/kg BW insulin (Actrapid 100 U/ml; Novo Nordisk,
Denmark). The effects of insulin were compared with
those in animals that received a saline injection (n = 4
ZDF rats, n = 4 ZL rats). After a 6 h fast and after thirty
minutes of saline or insulin injection, rats were killed by
decapitation. Trunk blood was collected for plasma deter-
minations. Hearts were removed and either snap-frozen
in dry-ice-chilled isopentane, liquid nitrogen or fixed in
4% formalin for further biochemical and histological
analysis.Cardiovascular Diabetology 2009, 8:39 http://www.cardiab.com/content/8/1/39
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Echocardiography
Echocardiography (ALOKA ProSound SSD 4000, Aloka,
Tokyo, Japan) was performed as described previously
[14]. Briefly, rats were anaesthetised with 3% isoflurane
via an induction chamber, and maintenance was per-
formed by 1.5–1.8% isoflurane and 0.6 L/min O2
throughout the procedure via spontaneous breathing.
Heart rate (HR) was kept relatively constant throughout
the procedure. All parameters were averaged over at least
three cardiac contractile cycles. Wall thickness (WT) and
LV-dimensions during end-systole (ESD) and end-dias-
tole (EDD) were determined in the B-(brightness) mode
of the parasternal short-axis view at the level of the papil-
lary muscles. Left ventricular (LV) systolic function was
calculated by 3 independent parameters; 1) fractional
shortening (FS), which was calculated by the equation: FS
(%) = (EDD-ESD)/EDD·100, 2) LV ejection time (ET),
calculated from the aorta flow waveform obtained from
the apical five-chamber view by measuring the interval
from the beginning of acceleration to the end of decelera-
tion, and 3) by the systolic excursion of the mitral annulus
(MAPSE), a measurement for the displacement of the
mitral annulus, which was measured by M-(motion)
mode echocardiography of the apical four-chamber view.
LV diastolic function was assessed by pulsed wave Dop-
pler analyses. Early transmitral peak diastolic flow velocity
(E-wave), deceleration time of the E-wave (Edec) and iso-
volumic relaxation time (IVRT) were obtained from the
apical four-chamber view. Peak early (E') diastolic tissue
velocity was recorded using Tissue Doppler Imaging at the
lateral side of the mitral annulus. Cardiac index (CI) and
LV mass index (LVMI) were determined as described pre-
viously [14]. Analyses were performed off-line (Image-
Arena 2.9.1, TomTec Imaging Systems, Untersch-
leissheim/Munich, Germany).
Cannulation of the jugular vein and femoral artery
Directly after echocardiography, catheters were placed in
the jugular vein and femoral artery under Hypnorm (0.5
ml/kg; Janssen Pharmaceutics, Beerse, Belgium; fentanyl
citrate 0.315 mg/ml, fluanisone 10 mg/ml) and Dormi-
cum (0.8 ml/kg; Midazolam, Roche, Woerden, The Neth-
erlands) anaesthesia. Insulin, glucose and PET tracers
were administered via the jugular vein, and the femoral
artery was used for blood sampling. After surgery, rats
were allowed to recover for a period of 3–5 days.
Myocardial positron emission tomography
After a 10 h fast, anaesthesia was induced using 3.5–4.0%
isoflurane, and maintained throughout the entire scan-
ning procedure using 2.0–3.0% isoflurane and 1.0 L/min
via spontaneous breathing. PET studies were performed
on a high resolution research tomograph (HRRT; CTI/Sie-
mens, Knoxville, TN) with an intrinsic spatial resolution
of <3.0 mm full width at half maximum over the whole
field of view [15]. For measurement of myocardial FA
metabolism, 15.3 ± 0.6 MBq of [11C]palmitate was
injected and flushed with 0.2 ml citrate buffer (0.01 mM)
followed by a 1 h emission scan. After a 3 h wait to allow
for radioactive decay of 11C, 13.4 ± 0.7 MBq of 18FDG was
injected followed by a 1 h emission scan for measurement
of myocardial glucose metabolism. This scan was per-
formed during the steady-state of a hyperinsulinaemic
euglycaemic clamp. For both tracers, data were sorted into
21 frames (1 × 30, 7 × 10, 1 × 20, 2 × 30, 2 × 60, 2 × 150,
2 × 300 and 4 × 600s). Prior to both scans, a 6 min trans-
mission scan was acquired in order to correct for tissue
attenuation. After completion of the PET study, animals
were killed by decapitation under isoflurane anaesthesia.
Hyperinsulinaemic euglycaemic clamp
The hyperinsulinaemic euglycaemic clamp was initiated
by 3 minutes insulin priming at an infusion rate of 120
mU/kg/min (Actrapid Penfill®, Novo Nordisk, Denmark),
followed by constant infusion of insulin at a rate of 12
mU/kg/min. Blood glucose (BG) concentrations were
determined every 5 minutes. Simultaneously, a 20% glu-
cose solution was infused at a variable rate to maintain
euglycaemia (BG 5.5 ± 0.1 mmol/L). Glucose clearance
(M-value, mg/kg/min) was calculated as the average glu-
cose infusion rate during the last 30 minutes.
Analysis of PET data
PET data were reconstructed using a partial volume cor-
rected – ordered subset expectation maximisation (PVC-
OSEM) algorithm [16], leading to an expected effective
spatial resolution in the images of ~2.0 mm. Recon-
structed images consisted of 256 × 256 × 207 voxels,
whereby one voxel measures 1.2 mm in each direction.
Regions of interest (ROIs) were placed over the LV cavity
and the myocardium in three image planes and decay cor-
rected time-activity curves (TACs) were obtained (AMIDE
0.8.22, amide.sourceforge.net). Regions near the liver
were avoided to prevent spillover to the heart. Myocardial
[11C]palmitate oxidation rate was derived from a biexpo-
nential fit to the TAC (Figure 1A), excluding data points
measured before the myocardial uptake reached a maxi-
mum. The myocardial oxidation rate equals ln(2) times
the inverse of the time constant of the fast exponential
[17]. Quantification of myocardial 18FDG utilisation was
achieved with compartment analysis, based on a two-tis-
sue compartment model (Figure 1B). The input function
was derived from a ROI drawn in three consecutive mid-
ventricular slices, with 4 voxels per plane as centrally
placed in the cavity as possible. A constant factor of 1.6
was used for the activity concentration ratio between
whole blood and plasma. The value of Ki, which repre-
sents the fractional rate of tracer influx, was obtained
using: Ki = K1·k3/(k2+k3), where K1 and k2 are rate con-
stants for forward and reverse capillary transport of 18FDGCardiovascular Diabetology 2009, 8:39 http://www.cardiab.com/content/8/1/39
Page 4 of 12
(page number not for citation purposes)
In vivo alterations in myocardial substrate metabolism Figure 1
In vivo alterations in myocardial substrate metabolism. Myocardial [11C]palmitate time-activity curve, where the rapid 
decline reflects clearance of palmitate from the myocardium (A). Two-tissue compartment model used for determining myo-
cardial metabolic rate of glucose utilisation (MMRglu) (B). Typical example of a myocardial [11C]palmitate and 18FDG image in 
a ZL and ZDF rat normalised for standard uptake value (summed images from 30 to 60 min) (C). Myocardial fatty acid (FA) 
oxidation rate constant measured under fasting conditions (D), and MMRglu measured under hyperinsulinaemic euglycaemic 
clamp conditions (E) for ZL rats (open bars) and ZDF rats (filled bars). Data are expressed as mean ± SEM, n = 6–11, * p < 
0.05 vs. ZL rats.
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and k3 refers to the rate of phosphorylation of 18FDG, as
illustrated in figure 1B. The myocardial metabolic rate of
glucose utilisation (MMRglu) is then given by MMRglu =
Ki·Cglu, where Cglu is the BG concentration.
Force measurements in isolated cardiomyocytes
Force measurements were performed in single, mechani-
cally isolated cardiomyocytes as described previously
[18]. Briefly, LV samples (frozen after saline injection)
were defrosted in relaxing solution (free Mg 1, KCl 100,
EGTA 2, Mg-ATP 4 and imidazole 10 mmol/L; pH 7.0),
mechanically disrupted and incubated for 5 minutes in
relaxing solution supplemented with 0.5% Triton X-100
to remove all membrane structures. Subsequently, cells
were washed twice in relaxing solution. Thereafter, a sin-
gle cardiomyocyte was attached between a force trans-
ducer and a piezoelectric motor (Figure 2A). Resting
sarcomere length of isolated cardiomyocytes was 1.8 μm
and was adjusted to 2.2 μm for measurements of isomet-
ric force. The pCa (-10log [Ca2+]) ranged from 9.0 (relax-
ation solution) to 4.5 (maximal activation). All force
values were normalised for cardiomyocyte cross-sectional
area. The cardiomyocyte was transferred from relaxing to
activating solution and the isometric force started to
develop. Once a steady-state force level was reached, the
cell was shortened to 80% of its original length within a
period of 1 ms to determine the base line of the force
transducer. The distance between baseline and steady-
state force level is the total force (Ftotal). After 20 ms the
cell was stretched again and returned to the relaxing solu-
tion, in which a second slack-test of 10 seconds duration
was performed to determine passive force (Fpassive). The
difference between Ftotal and Fpassive is the maximal force
(Fmax) developed by the cardiomyocyte. Rate of force rede-
velopment was determined at maximal activation (Ktr
max) using the slack-test as described previously [19].
Plasma measurements
Plasma hematocrit levels were determined using micro-
centrifugation. BG levels (Precision Xceed Blood Glucose
monitoring system, MediSense, UK), plasma insulin
(LINCO research, St. Charles, Missouri), plasma FA
(WAKO NEFA-C, Wako Pure Chemical Industries, Osaka,
Japan) and plasma triglyceride (TG; Sigma, Saint Louis,
Missouri) levels were measured from trunk blood as
described previously [14,20].
In vitro function of single cardiomyocytes Figure 2
In vitro function of single cardiomyocytes. Single cardiomyocyte mounted between a force transducer and piezoelectric 
motor (A). Maximal (Fmax) and passive (Fpassive) force (B), maximal rate of force redevelopment (Ktr max) (C) and calcium sen-
sitivity (D) in ZL rats (open bars) and ZDF rats (filled bars). Data are expressed as mean ± SEM, n = 4, * p < 0.005.
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Real-time PCR
Total RNA was extracted from 30 mg frozen LV tissue
(saline injected rats). After proteinase-K treatment and
DNase-digestion, RNA was purified using RNeasy mini
colums (Qiagen, Venlo, The Netherlands) as previously
described [21]. A total of 1 μg RNA was transcribed into
complementary DNA using a superscript™ first strand syn-
thesis kit (Invitrogen, Breda, The Netherlands) using
oligo-dT priming. mRNA abundance was measured using
a StepOne Plus real-time PCR system (Applied Biosys-
tems, Carlsbad, CA). Glucose transporter-4 (GLUT4) rat
specific primer pairs were designed using Primer Express
software (version 3.0; Applied Biosystems, Carlsbad, CA)
and are listed in the additional file 1. Reactions were car-
ried out as previously described [21]. All mRNA expres-
sion levels were expressed relative to EF1a and HPRT
abundance.
Protein analysis
LV biopsies were homogenised to obtain cellular protein
fractions for western blot analysis as previously described
[14]. Phosphorylation and/or expression of signaling
intermediates were analysed using the following primary
antibodies: phospho-Akt-Ser473, AMP activated protein
kinase  α1/2 (AMPKα1/2), phospho-AMPKα1/2-Thr172
(all Cell signaling Technology, Beverly, MA), pyruvate
dehydrogenase kinase-4 (PDK4; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), Akt2, phospho-phospholamban-
Ser16 (phospho-PLB-Ser16) (both Upstate, Lake Placid,
NY), Glucose transporter 4 (GLUT4; Abcam, Cambridge,
MA) and FA transporter (FAT)/CD36 (MO25) [14]. Sarco-
plasmic reticulum calcium ATPase 2a (SERCA2a) was
kindly provided by Dr. W. Simonides (VU University
Medical centre, Amsterdam, The Netherlands). All signals
were normalised to actin (Sigma, Saint Louis, Missouri).
Immunoblots were quantified by densitometric analysis
of films (AIDA, 4.21.033, Raytest, Strau-benhardt Ger-
many).
Histology
LV tissue from the free wall at the level of the papillary
muscles was fixed in 4% formalin and embedded in par-
affin. Sections (4 μm) were cut in the direction of the fib-
ers, and mounted on 3-aminopropyltriethoxisilane-
coated slides (Superfrost® Plus, Menzal, Darmstadt, Ger-
many). After deparaffinisation and rehydration, immuno-
histochemical staining and determination of the of the
abundance of FAT/CD36 at the sarcolemma was per-
formed as described before [14].
Statistical analysis
All data are presented as mean ± SEM. Between group
comparisons were performed using Student t-test. Two-
way ANOVA with Bonferroni post-hoc analysis was used
for group comparisons. Correlations were calculated by
the Pearson's test. p < 0.05 was considered as significant.
Results
T2DM phenotype
ZDF rats showed increased caloric intake and BW in com-
parison with age matched ZL controls (Table 1). Further-
more, ZDF rats were hyperglycaemic as reflected by
increased BG levels and water intake relative to ZL con-
trols. No differences were found in hematocrit levels
between animal groups. Plasma levels of insulin and TG
were increased 6- and 4-fold, respectively, in ZDF vs. ZL
rats, while plasma FA levels were similar in both groups.
Steady-state clamp BG levels were comparable in both
groups (5.6 ± 0.1 and 5.4 ± 0.1 mmol/L for ZDF and ZL
groups, respectively), whereas the M-value was signifi-
cantly lower in ZDF vs. ZL rats (Table 1).
Myocardial function in vivo and in vitro
In vivo B-mode echocardiography revealed increased LV
lumen diameter and reduced wall thickness during systole
in ZDF versus ZL rats (Table 2). LVMI was comparable in
both groups. Systolic functional abnormalities in ZDF rel-
ative to ZL rats were demonstrated by 3 independent
parameters, i.e. reduced FS, MAPSE, and prolonged ET
(Table 2). No differences were found in CI. ZDF vs. ZL rats
showed prolonged IVRT, E deceleration time, decreased E-
wave and decreased E', collectively indicating impaired LV
relaxation and filling (Table 2).
In vitro single cardiomyocytes from ZDF vs. ZL rats
showed significant decreases in Fmax (Figure 2B) and ktr
max (Figure 2C), whereas both groups showed compara-
ble Fpas (Figure 2B) and calcium sensitivity of the myofila-
ments (Figure 2D).
Myocardial substrate metabolism
Figure 1C shows typical myocardial [11C]palmitate and
18FDG images (summed images from 30 to 60 min) in a
ZDF and ZL rat. Myocardial FA oxidation rate was signifi-
cantly increased in ZDF animals as compared to ZL rats
Table 1: Characteristics of ZL (+/+) and ZDF (fa/fa) rats at 14 
weeks of age
ZL (+/+) ZDF (fa/fa)
Caloric intake [kcal/wk/100 grBW] 149 ± 5 229 ± 12*
Body weight at killing [g] 296 ± 5 349 ± 4*
Water intake [ml/wk/100 grBW] 65 ± 5 264 ± 17*
Non-fasting BG [mmol/L] 5.4 ± 0.2 20.1 ± 1.0*
Hematocrit [%] 49.7 ± 1.6 54.4 ± 1.7
Fasting insulin [pmol/L] 66.0 ± 5.8 387.8 ± 74.4*
Fasting TG [mmol/L] 0.58 ± 0.07 2.11 ± 0.54*
Fasting FA [mmol/L] 0.62 ± 0.05 0.58 ± 0.05
M-value [mg/kg/min] 21.2 ± 1.2 8.4 ± 0.7 *
Data are presented as mean ± SEM, n = 8–10, * p < 0.05 vs. ZL rats.
ZL, Zucker lean; ZDF, Zucker diabetic fatty; BG, blood glucose; TG, 
triglyceride; FA, fatty acid.Cardiovascular Diabetology 2009, 8:39 http://www.cardiab.com/content/8/1/39
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(Figure 1D), whereas MMRglu was significantly lower in
ZDF versus ZL animals (Figure 1E).
Molecular alterations in ZDF versus ZL rats
GLUT4 mRNA and protein expression were reduced by
68% (p < 0.05) and 22% (p = 0.10), respectively, in ZDF
versus ZL hearts (Figure 3A and 3B). PDK4 was compara-
ble in both groups (Figure 3C), whereas phosphorylation/
total protein ratio of AMPKα1/2 was significantly
decreased in ZDF vs. ZL hearts (Figure 3D). In the absence
of changes in total expression levels, histological analyses
(Figure 3E) showed a 2.4-fold increase (p < 0.01) in the
sarcolemmal abundance of FAT/CD36 in ZDF hearts
(31.0 ± 2.5%) as compared to ZL hearts (12.9 ± 1.0%),
indicative for increased FA uptake.
ZDF versus ZL hearts showed a significant decrease in
myocardial insulin-mediated Akt-Ser473 phosphoryla-
tion (Figure 4), whereas no differences were found in
basal phosphorylation. Finally, intracellular signaling
molecules related to myocardial calcium handling, like
PLB and SERCA2a were studied. No difference was found
in SERCA2a protein expression (see additional file 2A).
Basal phosphorylation of PLB-ser16, however, was
decreased in ZDF compared to ZL hearts, although it
failed to reach significance (p = 0.08, see additional file
2B).
Association between myocardial metabolism and function
Whole-body insulin sensitivity was significantly associ-
ated with in vivo fractional shortening, a measure for
systolic function (r = 0.83, p < 0.001; Figure 5A) and
inversely related to E deceleration time, a measure for
diastolic function (r = -0.62, p < 0.05; Figure 5B). No asso-
ciation was found between FA oxidation and myocardial
function. In contrast, MMRglu was strongly associated
with fractional shortening (r = 0.91, p < 0.005; Figure 5C)
and showed a trend to be inversely associated with E
deceleration time (r = -0.70, p = 0.08; Figure 5D).
Discussion
This study demonstrates alterations in myocardial sub-
strate metabolism and impaired myocardial function in a
rat model of early DCM. In particular, using in vivo PET
and echocardiography, our data extend previous in vitro
studies that assessed function [12,13], metabolism [22] or
both [9,10]. In particular, the present data showed
increased myocardial FA oxidation with a concomitant
decrease in insulin-mediated myocardial glucose utilisa-
tion. In addition, changes in myocardial function were
associated with systemic insulin sensitivity and reduced
myocardial glucose utilisation, whereas no relation was
found between function and myocardial FA oxidation.
Emerging evidence supports the concept that alterations
in myocardial substrate metabolism contribute to myo-
cardial dysfunction. In this regard it is conceivable that
alterations in substrate metabolism and underlying
molecular changes precede the development of overt
myocardial function. Previously, the earliest reported
time point at which there was evidence of heart failure in
ZDF rats was at 20 weeks of age [13], 6 weeks after the age
of the rats reported here. In addition to metabolic altera-
tions, echocardiographic diastolic and systolic functional
impairment and in vitro myofilament dysfunction in iso-
lated cardiomyocytes were found. Impaired myocardial
carbohydrate utilisation in the absence of systolic dys-
function in 11-weeks-old ZDF rats has been observed
using  13C-nuclear magnetic resonance [10], while at 12
weeks of age, ZDF rats have shown increased FA oxidation
and decreased carbohydrate oxidation in isolated hearts
with depressed systolic function [9], suggesting that
changes in myocardial substrate metabolism precede
myocardial dysfunction. The present in vivo data demon-
strate that myocardial glucose utilisation, but not FA oxi-
dation, is associated with both diastolic and systolic
function. Thus, myocardial dysfunction seems closely
related to the severity of altered myocardial substrate
metabolism in early diabetes.
The information provided by in vitro studies regarding
myocardial substrate metabolism in relation to myocar-
dial function is restricted by experimental conditions. In
Table 2: Echocardiographic parameters of ZL (+/+) and ZDF (fa/
fa) rats
ZL (+/+) ZDF (fa/fa)
Heart rate [bpm] 303 ± 13 301 ± 7
LV mass index [mg/g] 3.0 ± 0.14 2.8 ± 0.11
LV dimensions
ED lumen diameter [mm] 7.8 ± 0.2 7.9 ± 0.1
ES lumen diameter [mm] 3.2 ± 0.1 4.3 ± 0.1*
Diastolic WT [mm] 1.6 ± 0.03 1.7 ± 0.04
Systolic WT [mm] 3.3 ± 0.07 2.8 ± 0.06*
ED diameter [mm] 11.0 ± 0.2 11.1 ± 0.1
ES diameter [mm] 9.6 ± 0.4 10.2 ± 0.1
Systolic parameters
Fractional shortening [%] 58.7 ± 1.3 44.8 ± 1.2*
Ejection time [ms] 82.3 ± 1.8 89.9 ± 1.6*
MAPSE [mm] 2.1 ± 0.09 1.5 ± 0.06*
Cardiac index [ml/min/g] 0.29 ± 0.02 0.27 ± 0.02
Diastolic parameters
IVRT [ms] 26.7 ± 2.3 39.6 ± 2.3*
E deceleration time [ms] 38.4 ± 2.2 54.4 ± 3.0*
E wave [cm/s] 116.6 ± 4.2 98.7 ± 2.3*
E' [cm/s] 9.4 ± 0.3 8.4 ± 0.4‡
Data are presented as mean ± SEM, n = 12, * p < 0.01 and ‡ P = 0.07 
vs. ZL rats.
ZL, Zucker lean; ZDF, Zucker diabetic fatty; LV, left ventricle; ED, 
end-diastolic; ES, end-systolic; WT, wall thickness; MAPSE, mitral 
annulus plane systolic excursion; IVRT, isovolumic relaxation time.Cardiovascular Diabetology 2009, 8:39 http://www.cardiab.com/content/8/1/39
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Molecular alterations in ZDF hearts Figure 3
Molecular alterations in ZDF hearts. Quantification of glucose transporter-4 (GLUT4) mRNA levels (A) and protein levels 
(B), pyruvate dehydrogenase 4 (PDK4) protein levels (C) and phosphorylation/total protein levels of AMP kinase a (AMPKα1/
2-Thr172) (D) in ZL rats (open bars) and ZDF rats (filled bars). Protein expression and a typical example of subcellular locali-
sation of the fatty acid transporter (FAT)/CD36 (E) in ZL rats and ZDF rats. Data are expressed as mean ± SEM, n = 4–8, * p 
< 0.05, # p = 0.10.
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most studies, the choice of substrate concentrations may
not truly reflect what the heart utilises in vivo. In contrast,
PET provides a means for directly measuring true substrate
metabolism in vivo. Here, [11C]palmitate and 18FDG PET
were used to assess myocardial FA and glucose metabo-
lism under fasting and hyperinsulinaemic euglycaemic
clamp conditions, respectively. Previously, [11C]palmitate
PET was performed in 12-weeks-old ZDF rats [22], show-
ing increased FA oxidation. In spite of a reciprocal rela-
tionship between FA en glucose utilisation in the heart
[1,3,4], increased myocardial glucose utilisation meas-
ured with [11C]glucose was reported. In contrast, the same
research group, now using 18FDG PET, found a decrease in
myocardial glucose uptake rate and utilisation in 19-
weeks-old ZDF rats [23], possibly due to the difference in
age and in glucose tracer. These differences might also be
explained by the conditions under which glucose utilisa-
tion was measured, i.e. under fasting conditions, resulting
in FA being the primary substrate for myocardial energy.
In contrast, in the present study glucose utilisation was
measured using 18FDG under controlled hyperinsulinae-
mic euglycaemic conditions, as it is known that these con-
ditions yield the best 18FDG image quality and the highest
glucose utilisation in comparison with a glucose load or
an insulin bolus [24,25]. Taking this approach, increased
FA oxidation and decreased glucose utilisation were
found in this early stage of DCM in the hearts of ZDF rats.
In agreement with physiological data, impaired myocar-
dial insulin sensitivity in ZDF hearts was demonstrated by
an impaired ability of insulin to phosphorylate Akt. Sim-
ilar results were reported in hearts from high-fat diet fed
rats [20], Zucker rats [26] and ob/ob mice [27], whereby
the latter showed that impaired insulin signaling is asso-
ciated with alterations in myocardial glucose metabolism
measured in isolated working hearts. Further, we showed
that systemic insulin sensitivity, measured as whole-body
insulin sensitivity (M-value), was significantly associated
with in vivo systolic and diastolic function. Also, myocar-
dial insulin sensitivity, measured as insulin-mediated
myocardial glucose utilisation, correlated with systolic
and diastolic function. To the best of our knowledge, this
is the first report in rats showing an association between
in vivo function and in vivo myocardial metabolism. The
myocardium is a metabolic omnivore that under healthy
conditions will rely on FA oxidation for the largest part of
its ATP production. However, as glucose is the more ener-
getically efficient substrate, the myocardium should be
readily able to switch to glucose under conditions of stress
(e.g. ischemia, myocardial functional impairment such as
in heart failure). As insulin resistance impacts on myocar-
dial substrate supply (e.g. by increasing triglyceride-rich
lipoprotein- and glucose output from the liver and adi-
pose tissue-derived free fatty acids through unsuppressed
lipolysis), it is clear that both systemic and organ-specific
impairment of insulin action will influence substrate uti-
lisation and reduce myocardial "metabolic flexibility"
[28-31]. Thus, in the stressed heart insulin resistance may
finally hamper energy metabolism and as such myocar-
dial function [28,29,31]. Conversely, improvement of
insulin sensitivity may ameliorate myocardial function. In
humans, Iozzo et al. found an inverse association of myo-
cardial insulin-mediated glucose utilisation and systolic
function [31]. Our group showed that the insulin sensi-
tizer pioglitazone improved whole-body insulin sensitiv-
ity and insulin-mediated myocardial glucose utilisation
together with an improvement in myocardial diastolic
function in patients with well-controlled T2DM [29].
These findings support the role of insulin sensitivity in
myocardial metabolism and function in DCM.
A restriction to glucose utilisation in the diabetic heart is
the slow rate of glucose transport across the sarcolemmal
membrane into the myocardium [32]. In line with previ-
ous reports [6,33], decreased GLUT4 expression was
found. PDK4 has an inhibitory effect on glucose oxidation
via the pyruvate dehydrogenase complex (PDH) [34],
however, no differences were found in PDK4 protein
expression. Similar PDK4 mRNA levels were found in ZDF
rats [6] and Zucker rats [5]. However, Chatham et al. [10]
showed increased PDH activity in ZDF hearts. AMPK is
known as a major regulator of metabolic myocardial
energy substrate acting as a metabolic sensor following an
energetic imbalance. Decreased AMPKα1/2 phosphoryla-
Molecular alterations in myocardial insulin signaling Figure 4
Molecular alterations in myocardial insulin signaling. 
Quantification of immunoblots showing relative phosphoryla-
tion/total protein levels of Akt-Ser473/Akt2 after saline (-; 
open bars) or insulin (+; filled bars) injection. Data are 
expressed as mean ± SEM, n = 4–8, * p < 0.05 different from 
basal, # p < 0.05 different from ZL.
Akt-Ser473p
ZDF ZL
Akt2
- +            - +
ZL ZDF
0.0
0.5
1.0
1.5
saline
insulin
#
#
*
R
e
l
a
t
i
v
e
 
p
-
A
k
t
-
S
e
r
4
7
3
/
A
k
t
2
r
a
t
i
o
 
(
%
)Cardiovascular Diabetology 2009, 8:39 http://www.cardiab.com/content/8/1/39
Page 10 of 12
(page number not for citation purposes)
tion was found, which is consistent with previous results
[35,36]. In addition, a significant increase in sarcolemmal
localisation of the FA transporter FAT/CD36 in ZDF hearts
was seen, which is compatible with the observed enhance-
ment of myocardial FA oxidation. These data are in line
with those reported in high-fat diet fed [14] and Zucker
[37,38] rats, in both of which relocation of FAT/CD36 to
the sarcolemmal membrane was associated with
increased myocardial FA uptake. Collectively, these
molecular findings are compatible with the measured
shift in myocardial substrate metabolism towards
increased myocardial FA metabolism and decreased myo-
cardial glucose metabolism.
In isolated cardiomyocytes of ZDF rats, significant reduc-
tions were observed in both maximal force and maximal
rate of force redevelopment. A previous study by Ren et al.
[39] showed reduction in peak shortening, prolonged
duration of re-lengthening and unaltered resting intracel-
lular calcium levels in intact cardiomyocytes from 14-
weeks-old Zucker rats. The reduction in maximal force
generating capacity of myofilaments observed in the
present study may well explain reduced cardiomyocyte
shortening. Moreover, the reduction in maximal rate of
force redevelopment may, at least in part, underlie pro-
longed duration of cellular re-lengthening (i.e. cardiomy-
ocyte relaxation). No differences were found in calcium
sensitivity as well as SERCA2a expression. However, a
trend towards decreased phosphorylation of phos-
pholamban was found. Hence, cellular dysfunction in
early DCM could be the result of myofilament dysfunc-
tion. Nevertheless, the exact mechanisms leading to
depressed myocardial function in early diabetes remain
elusive. Several potential options to be responsible for the
pathogenesis of myocardial dysfunction in early diabetes
have been postulated, including (1) lipotoxicity via cera-
mide dependent pathways, (2) increased accumulation of
advanced glycation end products, and (3) generation of
reactive oxygen species via increased flux through mito-
chondrial pathways. Further studies are necessary to
reveal the exact transition from compensatory myocardial
function to overt myocardial dysfunction during altera-
tions in myocardial substrate metabolism.
Association between metabolism and function Figure 5
Association between metabolism and function. Relationship of whole-body insulin sensitivity (M-value) with fractional 
shortening (A; r = 0.83, p < 0.001, n = 12) and E deceleration time (B; r = -0.62, p < 0.05, n = 12). Relationship of myocardial 
metabolic rate of glucose utilisation (MMRglu) with fractional shortening (C; r = 0.91, p < 0.005, n = 7) and E deceleration time 
(D; r = -0.70, p = 0.08, n = 7).
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Conclusion
Using combined in vivo measurements of myocardial sub-
strate metabolism and function by state-of-the-art PET
and echocardiography, respectively, we found increased
myocardial FA oxidation under fasting and decreased
insulin-mediated glucose utilisation under (hyperinsuli-
naemic) isoglycaemic conditions as well as a reduced
systolic and diastolic function in early experimental DCM.
Furthermore, myocardial glucose utilisation was associ-
ated with myocardial function. At the molecular level, the
alterations in myocardial substrate metabolism were par-
alleled by a decreased expression of GLUT4 and increased
sarcolemmal abundance of FAT/CD36. Finally, the
observed association between impaired systemic and
myocardial insulin sensitivity and myocardial dysfunc-
tion supports the notion that alterations in myocardial
substrate supply and metabolism may affect the course of
DCM.
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